世界各国のリアルタイムなデータ・インテリジェンスで皆様をお手伝い

降圧剤の世界市場シェアとランキング、全体売上高と需要予測 2025-2031

降圧剤の世界市場シェアとランキング、全体売上高と需要予測 2025-2031


Antihypertensive Agents- Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031

降圧剤の世界市場は、2024年には100万米ドル規模になると推定され、2031年には100万米ドルに再調整され、予測期間2025-2031年の年平均成長率は%になると予測されています。 世界の医薬品市場は2022年に1,475億... もっと見る

 

 

出版社 出版年月 電子版価格 納期 言語
QYResearch
QYリサーチ
2025年3月21日 US$3,950
シングルユーザライセンス
ライセンス・価格情報
注文方法はこちら
5-7営業日 英語

※当ページの内容はウェブ更新時の情報です。
最新版の価格やページ数などの情報についてはお問合せください。

日本語のページは自動翻訳を利用し作成しています。
実際のレポートは英文のみでご納品いたします。


 

サマリー

降圧剤の世界市場は、2024年には100万米ドル規模になると推定され、2031年には100万米ドルに再調整され、予測期間2025-2031年の年平均成長率は%になると予測されています。

世界の医薬品市場は2022年に1,475億米ドルとなり、今後6年間のCAGRは5%で成長する。医薬品市場には、化学医薬品と生物学的製剤が含まれる。生物製剤は2022年に3810億米ドルになると予想されている。これに対し、化学医薬品市場は2018年の1,050億米ドルから2022年には1,090億米ドルに増加すると推定されている。医薬品市場の要因としては、医療需要の増加、技術の進歩、慢性疾患の有病率の上昇、医薬品製造分野の開発に対する民間&政府機関からの資金提供の増加、医薬品の研究開発活動の活発化などが挙げられる。しかし、厳しい規制、研究開発費の高騰、特許切れといった課題にも直面している。企業は、市場での競争力を維持し、必要とする患者に確実に製品を届けるために、継続的に技術革新を行い、こうした課題に適応していく必要がある。さらに、COVID-19の大流行はワクチン開発とサプライチェーン・マネジメントの重要性を浮き彫りにし、製薬企業が新たな公衆衛生のニーズに機敏に対応する必要性をさらに強調している。

本レポートは、地域・国別、タイプ別、用途別の降圧剤の分析とともに、総売上高、主要企業の市場シェア、ランキングに焦点を当て、降圧剤の世界市場を包括的に紹介することを目的としています。
降圧剤の市場規模、推計、予測は、2024年を基準年として、2020年から2031年までの期間の履歴データと予測データを売上高(百万ドル)で提供します。定量的および定性的な分析により、読者がビジネス/成長戦略を策定し、市場競争状況を評価し、現在の市場での地位を分析し、降圧剤に関する情報に基づいたビジネス上の意思決定を行うのに役立ちます。

市場区分
企業別
バクスターインターナショナル
ファイザー
サンド
テバ・ファーマシューティカルズ
バイエル
ジョンソン・エンド・ジョンソン
サン・ファーマシューティカル・インダストリーズ
メルク
アストラゼネカ
第一三共
武田薬品工業
アクテリオン
ヴィアトリス
ユナイテッド・セラピューティクス
ルパン
ヒクマ・ファーマシューティカルズ
オーロビンド・ファーマ
キャンバー・ファーマシューティカル
メジャー・ファーマシューティカルズ
グレンマーク製薬
ザイダス製薬
アムニール製薬
エンド・インターナショナル
ユニケム・ラボラトリーズ
華海製薬
石家荘製薬グループ
上海シンデック製薬
タイプ別セグメント
サイアザイド系利尿薬
カルシウム拮抗薬(CCB)
ACE阻害薬
アンジオテンシンII受容体拮抗薬(ARBs)
用途別セグメント
小児
成人
地域別
北米
米国
カナダ
アジア太平洋
中国
日本
韓国
東南アジア
インド
オーストラリア
その他のアジア太平洋地域
ヨーロッパ
ドイツ
フランス
英国
イタリア
オランダ
北欧諸国
その他のヨーロッパ
ラテンアメリカ
メキシコ
ブラジル
その他のラテンアメリカ
中東・アフリカ
トルコ
サウジアラビア
アラブ首長国連邦
その他のMEA

各章の概要
第1章: レポートのスコープ、世界の総市場規模を紹介します。本章ではまた、市場力学、市場の最新動向、市場の推進要因と制限要因、業界のメーカーが直面する課題とリスク、業界の関連政策の分析を提供します。
第2章:降圧剤企業の競争環境、収益市場シェア、最新の開発計画、合併・買収情報などを詳細に分析。
第3章:各種市場セグメントをタイプ別に分析し、各市場セグメントの市場規模や発展可能性を網羅し、読者が各市場セグメントにおけるブルーオーシャン市場を見つけやすくします。
第4章:用途別の様々な市場セグメントの分析を提供し、各市場セグメントの市場規模と発展可能性をカバーし、読者が異なる下流市場のブルーオーシャン市場を見つけるのを助ける。
第5章:地域レベルでの降圧剤の収益。各地域の市場規模と発展可能性を定量的に分析し、世界各国の市場発展、将来発展見込み、市場空間、市場規模を紹介しています。
第6章:降圧剤の国別収益。各国・地域のタイプ別、用途別のシグメイトデータを提供。
第7章:主要企業のプロファイルを提供し、製品収益、売上総利益率、製品紹介、最近の開発など、市場における主要企業の基本的な状況を詳細に紹介する。
第8章:産業の上流と下流を含む産業チェーンの分析。
第9章:結論


ページTOPに戻る


目次

1 Market Overview
1.1 Antihypertensive Agents Product Introduction
1.2 Global Antihypertensive Agents Market Size Forecast (2020-2031)
1.3 Antihypertensive Agents Market Trends & Drivers
1.3.1 Antihypertensive Agents Industry Trends
1.3.2 Antihypertensive Agents Market Drivers & Opportunity
1.3.3 Antihypertensive Agents Market Challenges
1.3.4 Antihypertensive Agents Market Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global Antihypertensive Agents Players Revenue Ranking (2024)
2.2 Global Antihypertensive Agents Revenue by Company (2020-2025)
2.3 Key Companies Antihypertensive Agents Manufacturing Base Distribution and Headquarters
2.4 Key Companies Antihypertensive Agents Product Offered
2.5 Key Companies Time to Begin Mass Production of Antihypertensive Agents
2.6 Antihypertensive Agents Market Competitive Analysis
2.6.1 Antihypertensive Agents Market Concentration Rate (2020-2025)
2.6.2 Global 5 and 10 Largest Companies by Antihypertensive Agents Revenue in 2024
2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Antihypertensive Agents as of 2024)
2.7 Mergers & Acquisitions, Expansion
3 Segmentation by Type
3.1 Introduction by Type
3.1.1 Thiazide Diuretics
3.1.2 Calcium Channel Blockers (CCB)
3.1.3 ACE Inhibitors
3.1.4 Angiotensin II Receptor Antagonists (ARBs)
3.2 Global Antihypertensive Agents Sales Value by Type
3.2.1 Global Antihypertensive Agents Sales Value by Type (2020 VS 2024 VS 2031)
3.2.2 Global Antihypertensive Agents Sales Value, by Type (2020-2031)
3.2.3 Global Antihypertensive Agents Sales Value, by Type (%) (2020-2031)
4 Segmentation by Application
4.1 Introduction by Application
4.1.1 Children
4.1.2 Adult
4.2 Global Antihypertensive Agents Sales Value by Application
4.2.1 Global Antihypertensive Agents Sales Value by Application (2020 VS 2024 VS 2031)
4.2.2 Global Antihypertensive Agents Sales Value, by Application (2020-2031)
4.2.3 Global Antihypertensive Agents Sales Value, by Application (%) (2020-2031)
5 Segmentation by Region
5.1 Global Antihypertensive Agents Sales Value by Region
5.1.1 Global Antihypertensive Agents Sales Value by Region: 2020 VS 2024 VS 2031
5.1.2 Global Antihypertensive Agents Sales Value by Region (2020-2025)
5.1.3 Global Antihypertensive Agents Sales Value by Region (2026-2031)
5.1.4 Global Antihypertensive Agents Sales Value by Region (%), (2020-2031)
5.2 North America
5.2.1 North America Antihypertensive Agents Sales Value, 2020-2031
5.2.2 North America Antihypertensive Agents Sales Value by Country (%), 2024 VS 2031
5.3 Europe
5.3.1 Europe Antihypertensive Agents Sales Value, 2020-2031
5.3.2 Europe Antihypertensive Agents Sales Value by Country (%), 2024 VS 2031
5.4 Asia Pacific
5.4.1 Asia Pacific Antihypertensive Agents Sales Value, 2020-2031
5.4.2 Asia Pacific Antihypertensive Agents Sales Value by Region (%), 2024 VS 2031
5.5 South America
5.5.1 South America Antihypertensive Agents Sales Value, 2020-2031
5.5.2 South America Antihypertensive Agents Sales Value by Country (%), 2024 VS 2031
5.6 Middle East & Africa
5.6.1 Middle East & Africa Antihypertensive Agents Sales Value, 2020-2031
5.6.2 Middle East & Africa Antihypertensive Agents Sales Value by Country (%), 2024 VS 2031
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions Antihypertensive Agents Sales Value Growth Trends, 2020 VS 2024 VS 2031
6.2 Key Countries/Regions Antihypertensive Agents Sales Value, 2020-2031
6.3 United States
6.3.1 United States Antihypertensive Agents Sales Value, 2020-2031
6.3.2 United States Antihypertensive Agents Sales Value by Type (%), 2024 VS 2031
6.3.3 United States Antihypertensive Agents Sales Value by Application, 2024 VS 2031
6.4 Europe
6.4.1 Europe Antihypertensive Agents Sales Value, 2020-2031
6.4.2 Europe Antihypertensive Agents Sales Value by Type (%), 2024 VS 2031
6.4.3 Europe Antihypertensive Agents Sales Value by Application, 2024 VS 2031
6.5 China
6.5.1 China Antihypertensive Agents Sales Value, 2020-2031
6.5.2 China Antihypertensive Agents Sales Value by Type (%), 2024 VS 2031
6.5.3 China Antihypertensive Agents Sales Value by Application, 2024 VS 2031
6.6 Japan
6.6.1 Japan Antihypertensive Agents Sales Value, 2020-2031
6.6.2 Japan Antihypertensive Agents Sales Value by Type (%), 2024 VS 2031
6.6.3 Japan Antihypertensive Agents Sales Value by Application, 2024 VS 2031
6.7 South Korea
6.7.1 South Korea Antihypertensive Agents Sales Value, 2020-2031
6.7.2 South Korea Antihypertensive Agents Sales Value by Type (%), 2024 VS 2031
6.7.3 South Korea Antihypertensive Agents Sales Value by Application, 2024 VS 2031
6.8 Southeast Asia
6.8.1 Southeast Asia Antihypertensive Agents Sales Value, 2020-2031
6.8.2 Southeast Asia Antihypertensive Agents Sales Value by Type (%), 2024 VS 2031
6.8.3 Southeast Asia Antihypertensive Agents Sales Value by Application, 2024 VS 2031
6.9 India
6.9.1 India Antihypertensive Agents Sales Value, 2020-2031
6.9.2 India Antihypertensive Agents Sales Value by Type (%), 2024 VS 2031
6.9.3 India Antihypertensive Agents Sales Value by Application, 2024 VS 2031
7 Company Profiles
7.1 Baxter International
7.1.1 Baxter International Profile
7.1.2 Baxter International Main Business
7.1.3 Baxter International Antihypertensive Agents Products, Services and Solutions
7.1.4 Baxter International Antihypertensive Agents Revenue (US$ Million) & (2020-2025)
7.1.5 Baxter International Recent Developments
7.2 Pfizer
7.2.1 Pfizer Profile
7.2.2 Pfizer Main Business
7.2.3 Pfizer Antihypertensive Agents Products, Services and Solutions
7.2.4 Pfizer Antihypertensive Agents Revenue (US$ Million) & (2020-2025)
7.2.5 Pfizer Recent Developments
7.3 Sandoz
7.3.1 Sandoz Profile
7.3.2 Sandoz Main Business
7.3.3 Sandoz Antihypertensive Agents Products, Services and Solutions
7.3.4 Sandoz Antihypertensive Agents Revenue (US$ Million) & (2020-2025)
7.3.5 Sandoz Recent Developments
7.4 Teva Pharmaceuticals
7.4.1 Teva Pharmaceuticals Profile
7.4.2 Teva Pharmaceuticals Main Business
7.4.3 Teva Pharmaceuticals Antihypertensive Agents Products, Services and Solutions
7.4.4 Teva Pharmaceuticals Antihypertensive Agents Revenue (US$ Million) & (2020-2025)
7.4.5 Teva Pharmaceuticals Recent Developments
7.5 Bayer
7.5.1 Bayer Profile
7.5.2 Bayer Main Business
7.5.3 Bayer Antihypertensive Agents Products, Services and Solutions
7.5.4 Bayer Antihypertensive Agents Revenue (US$ Million) & (2020-2025)
7.5.5 Bayer Recent Developments
7.6 Johnson & Johnson
7.6.1 Johnson & Johnson Profile
7.6.2 Johnson & Johnson Main Business
7.6.3 Johnson & Johnson Antihypertensive Agents Products, Services and Solutions
7.6.4 Johnson & Johnson Antihypertensive Agents Revenue (US$ Million) & (2020-2025)
7.6.5 Johnson & Johnson Recent Developments
7.7 Sun Pharmaceutical Industries
7.7.1 Sun Pharmaceutical Industries Profile
7.7.2 Sun Pharmaceutical Industries Main Business
7.7.3 Sun Pharmaceutical Industries Antihypertensive Agents Products, Services and Solutions
7.7.4 Sun Pharmaceutical Industries Antihypertensive Agents Revenue (US$ Million) & (2020-2025)
7.7.5 Sun Pharmaceutical Industries Recent Developments
7.8 Merck
7.8.1 Merck Profile
7.8.2 Merck Main Business
7.8.3 Merck Antihypertensive Agents Products, Services and Solutions
7.8.4 Merck Antihypertensive Agents Revenue (US$ Million) & (2020-2025)
7.8.5 Merck Recent Developments
7.9 AstraZeneca
7.9.1 AstraZeneca Profile
7.9.2 AstraZeneca Main Business
7.9.3 AstraZeneca Antihypertensive Agents Products, Services and Solutions
7.9.4 AstraZeneca Antihypertensive Agents Revenue (US$ Million) & (2020-2025)
7.9.5 AstraZeneca Recent Developments
7.10 Daiichi Sankyo
7.10.1 Daiichi Sankyo Profile
7.10.2 Daiichi Sankyo Main Business
7.10.3 Daiichi Sankyo Antihypertensive Agents Products, Services and Solutions
7.10.4 Daiichi Sankyo Antihypertensive Agents Revenue (US$ Million) & (2020-2025)
7.10.5 Daiichi Sankyo Recent Developments
7.11 Takeda
7.11.1 Takeda Profile
7.11.2 Takeda Main Business
7.11.3 Takeda Antihypertensive Agents Products, Services and Solutions
7.11.4 Takeda Antihypertensive Agents Revenue (US$ Million) & (2020-2025)
7.11.5 Takeda Recent Developments
7.12 Actelion
7.12.1 Actelion Profile
7.12.2 Actelion Main Business
7.12.3 Actelion Antihypertensive Agents Products, Services and Solutions
7.12.4 Actelion Antihypertensive Agents Revenue (US$ Million) & (2020-2025)
7.12.5 Actelion Recent Developments
7.13 Viatris
7.13.1 Viatris Profile
7.13.2 Viatris Main Business
7.13.3 Viatris Antihypertensive Agents Products, Services and Solutions
7.13.4 Viatris Antihypertensive Agents Revenue (US$ Million) & (2020-2025)
7.13.5 Viatris Recent Developments
7.14 United Therapeutics
7.14.1 United Therapeutics Profile
7.14.2 United Therapeutics Main Business
7.14.3 United Therapeutics Antihypertensive Agents Products, Services and Solutions
7.14.4 United Therapeutics Antihypertensive Agents Revenue (US$ Million) & (2020-2025)
7.14.5 United Therapeutics Recent Developments
7.15 Lupin Limited
7.15.1 Lupin Limited Profile
7.15.2 Lupin Limited Main Business
7.15.3 Lupin Limited Antihypertensive Agents Products, Services and Solutions
7.15.4 Lupin Limited Antihypertensive Agents Revenue (US$ Million) & (2020-2025)
7.15.5 Lupin Limited Recent Developments
7.16 Hikma Pharmaceuticals
7.16.1 Hikma Pharmaceuticals Profile
7.16.2 Hikma Pharmaceuticals Main Business
7.16.3 Hikma Pharmaceuticals Antihypertensive Agents Products, Services and Solutions
7.16.4 Hikma Pharmaceuticals Antihypertensive Agents Revenue (US$ Million) & (2020-2025)
7.16.5 Hikma Pharmaceuticals Recent Developments
7.17 Aurobindo Pharma
7.17.1 Aurobindo Pharma Profile
7.17.2 Aurobindo Pharma Main Business
7.17.3 Aurobindo Pharma Antihypertensive Agents Products, Services and Solutions
7.17.4 Aurobindo Pharma Antihypertensive Agents Revenue (US$ Million) & (2020-2025)
7.17.5 Aurobindo Pharma Recent Developments
7.18 Camber Pharmaceutical
7.18.1 Camber Pharmaceutical Profile
7.18.2 Camber Pharmaceutical Main Business
7.18.3 Camber Pharmaceutical Antihypertensive Agents Products, Services and Solutions
7.18.4 Camber Pharmaceutical Antihypertensive Agents Revenue (US$ Million) & (2020-2025)
7.18.5 Camber Pharmaceutical Recent Developments
7.19 Major Pharmaceuticals
7.19.1 Major Pharmaceuticals Profile
7.19.2 Major Pharmaceuticals Main Business
7.19.3 Major Pharmaceuticals Antihypertensive Agents Products, Services and Solutions
7.19.4 Major Pharmaceuticals Antihypertensive Agents Revenue (US$ Million) & (2020-2025)
7.19.5 Major Pharmaceuticals Recent Developments
7.20 Glenmark Pharmaceuticals
7.20.1 Glenmark Pharmaceuticals Profile
7.20.2 Glenmark Pharmaceuticals Main Business
7.20.3 Glenmark Pharmaceuticals Antihypertensive Agents Products, Services and Solutions
7.20.4 Glenmark Pharmaceuticals Antihypertensive Agents Revenue (US$ Million) & (2020-2025)
7.20.5 Glenmark Pharmaceuticals Recent Developments
7.21 Zydus Pharmaceuticals
7.21.1 Zydus Pharmaceuticals Profile
7.21.2 Zydus Pharmaceuticals Main Business
7.21.3 Zydus Pharmaceuticals Antihypertensive Agents Products, Services and Solutions
7.21.4 Zydus Pharmaceuticals Antihypertensive Agents Revenue (US$ Million) & (2020-2025)
7.21.5 Zydus Pharmaceuticals Recent Developments
7.22 Amneal Pharmaceuticals
7.22.1 Amneal Pharmaceuticals Profile
7.22.2 Amneal Pharmaceuticals Main Business
7.22.3 Amneal Pharmaceuticals Antihypertensive Agents Products, Services and Solutions
7.22.4 Amneal Pharmaceuticals Antihypertensive Agents Revenue (US$ Million) & (2020-2025)
7.22.5 Amneal Pharmaceuticals Recent Developments
7.23 Endo International
7.23.1 Endo International Profile
7.23.2 Endo International Main Business
7.23.3 Endo International Antihypertensive Agents Products, Services and Solutions
7.23.4 Endo International Antihypertensive Agents Revenue (US$ Million) & (2020-2025)
7.23.5 Endo International Recent Developments
7.24 Unichem Laboratories
7.24.1 Unichem Laboratories Profile
7.24.2 Unichem Laboratories Main Business
7.24.3 Unichem Laboratories Antihypertensive Agents Products, Services and Solutions
7.24.4 Unichem Laboratories Antihypertensive Agents Revenue (US$ Million) & (2020-2025)
7.24.5 Unichem Laboratories Recent Developments
7.25 Huahai Pharmaceutical
7.25.1 Huahai Pharmaceutical Profile
7.25.2 Huahai Pharmaceutical Main Business
7.25.3 Huahai Pharmaceutical Antihypertensive Agents Products, Services and Solutions
7.25.4 Huahai Pharmaceutical Antihypertensive Agents Revenue (US$ Million) & (2020-2025)
7.25.5 Huahai Pharmaceutical Recent Developments
7.26 Shijiazhuang Pharma Group
7.26.1 Shijiazhuang Pharma Group Profile
7.26.2 Shijiazhuang Pharma Group Main Business
7.26.3 Shijiazhuang Pharma Group Antihypertensive Agents Products, Services and Solutions
7.26.4 Shijiazhuang Pharma Group Antihypertensive Agents Revenue (US$ Million) & (2020-2025)
7.26.5 Shijiazhuang Pharma Group Recent Developments
7.27 Shanghai Shyndec Pharmaceutical
7.27.1 Shanghai Shyndec Pharmaceutical Profile
7.27.2 Shanghai Shyndec Pharmaceutical Main Business
7.27.3 Shanghai Shyndec Pharmaceutical Antihypertensive Agents Products, Services and Solutions
7.27.4 Shanghai Shyndec Pharmaceutical Antihypertensive Agents Revenue (US$ Million) & (2020-2025)
7.27.5 Shanghai Shyndec Pharmaceutical Recent Developments
8 Industry Chain Analysis
8.1 Antihypertensive Agents Industrial Chain
8.2 Antihypertensive Agents Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Raw Materials Key Suppliers
8.2.3 Manufacturing Cost Structure
8.3 Midstream Analysis
8.4 Downstream Analysis (Customers Analysis)
8.5 Sales Model and Sales Channels
8.5.1 Antihypertensive Agents Sales Model
8.5.2 Sales Channel
8.5.3 Antihypertensive Agents Distributors
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.1.1 Research Programs/Design
10.1.1.2 Market Size Estimation
10.1.1.3 Market Breakdown and Data Triangulation
10.1.2 Data Source
10.1.2.1 Secondary Sources
10.1.2.2 Primary Sources
10.2 Author Details
10.3 Disclaimer

 

ページTOPに戻る


 

Summary

The global market for Antihypertensive Agents was estimated to be worth US$ million in 2024 and is forecast to a readjusted size of US$ million by 2031 with a CAGR of %during the forecast period 2025-2031.

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

This report aims to provide a comprehensive presentation of the global market for Antihypertensive Agents, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Antihypertensive Agents by region & country, by Type, and by Application.
The Antihypertensive Agents market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Antihypertensive Agents.

Market Segmentation
By Company
Baxter International
Pfizer
Sandoz
Teva Pharmaceuticals
Bayer
Johnson & Johnson
Sun Pharmaceutical Industries
Merck
AstraZeneca
Daiichi Sankyo
Takeda
Actelion
Viatris
United Therapeutics
Lupin Limited
Hikma Pharmaceuticals
Aurobindo Pharma
Camber Pharmaceutical
Major Pharmaceuticals
Glenmark Pharmaceuticals
Zydus Pharmaceuticals
Amneal Pharmaceuticals
Endo International
Unichem Laboratories
Huahai Pharmaceutical
Shijiazhuang Pharma Group
Shanghai Shyndec Pharmaceutical
Segment by Type
Thiazide Diuretics
Calcium Channel Blockers (CCB)
ACE Inhibitors
Angiotensin II Receptor Antagonists (ARBs)
Segment by Application
Children
Adult
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia-Pacific
Europe
Germany
France
U.K.
Italy
Netherlands
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA

Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Antihypertensive Agents company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Revenue of Antihypertensive Agents in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Revenue of Antihypertensive Agents in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.



ページTOPに戻る


Table of Contents

1 Market Overview
1.1 Antihypertensive Agents Product Introduction
1.2 Global Antihypertensive Agents Market Size Forecast (2020-2031)
1.3 Antihypertensive Agents Market Trends & Drivers
1.3.1 Antihypertensive Agents Industry Trends
1.3.2 Antihypertensive Agents Market Drivers & Opportunity
1.3.3 Antihypertensive Agents Market Challenges
1.3.4 Antihypertensive Agents Market Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global Antihypertensive Agents Players Revenue Ranking (2024)
2.2 Global Antihypertensive Agents Revenue by Company (2020-2025)
2.3 Key Companies Antihypertensive Agents Manufacturing Base Distribution and Headquarters
2.4 Key Companies Antihypertensive Agents Product Offered
2.5 Key Companies Time to Begin Mass Production of Antihypertensive Agents
2.6 Antihypertensive Agents Market Competitive Analysis
2.6.1 Antihypertensive Agents Market Concentration Rate (2020-2025)
2.6.2 Global 5 and 10 Largest Companies by Antihypertensive Agents Revenue in 2024
2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Antihypertensive Agents as of 2024)
2.7 Mergers & Acquisitions, Expansion
3 Segmentation by Type
3.1 Introduction by Type
3.1.1 Thiazide Diuretics
3.1.2 Calcium Channel Blockers (CCB)
3.1.3 ACE Inhibitors
3.1.4 Angiotensin II Receptor Antagonists (ARBs)
3.2 Global Antihypertensive Agents Sales Value by Type
3.2.1 Global Antihypertensive Agents Sales Value by Type (2020 VS 2024 VS 2031)
3.2.2 Global Antihypertensive Agents Sales Value, by Type (2020-2031)
3.2.3 Global Antihypertensive Agents Sales Value, by Type (%) (2020-2031)
4 Segmentation by Application
4.1 Introduction by Application
4.1.1 Children
4.1.2 Adult
4.2 Global Antihypertensive Agents Sales Value by Application
4.2.1 Global Antihypertensive Agents Sales Value by Application (2020 VS 2024 VS 2031)
4.2.2 Global Antihypertensive Agents Sales Value, by Application (2020-2031)
4.2.3 Global Antihypertensive Agents Sales Value, by Application (%) (2020-2031)
5 Segmentation by Region
5.1 Global Antihypertensive Agents Sales Value by Region
5.1.1 Global Antihypertensive Agents Sales Value by Region: 2020 VS 2024 VS 2031
5.1.2 Global Antihypertensive Agents Sales Value by Region (2020-2025)
5.1.3 Global Antihypertensive Agents Sales Value by Region (2026-2031)
5.1.4 Global Antihypertensive Agents Sales Value by Region (%), (2020-2031)
5.2 North America
5.2.1 North America Antihypertensive Agents Sales Value, 2020-2031
5.2.2 North America Antihypertensive Agents Sales Value by Country (%), 2024 VS 2031
5.3 Europe
5.3.1 Europe Antihypertensive Agents Sales Value, 2020-2031
5.3.2 Europe Antihypertensive Agents Sales Value by Country (%), 2024 VS 2031
5.4 Asia Pacific
5.4.1 Asia Pacific Antihypertensive Agents Sales Value, 2020-2031
5.4.2 Asia Pacific Antihypertensive Agents Sales Value by Region (%), 2024 VS 2031
5.5 South America
5.5.1 South America Antihypertensive Agents Sales Value, 2020-2031
5.5.2 South America Antihypertensive Agents Sales Value by Country (%), 2024 VS 2031
5.6 Middle East & Africa
5.6.1 Middle East & Africa Antihypertensive Agents Sales Value, 2020-2031
5.6.2 Middle East & Africa Antihypertensive Agents Sales Value by Country (%), 2024 VS 2031
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions Antihypertensive Agents Sales Value Growth Trends, 2020 VS 2024 VS 2031
6.2 Key Countries/Regions Antihypertensive Agents Sales Value, 2020-2031
6.3 United States
6.3.1 United States Antihypertensive Agents Sales Value, 2020-2031
6.3.2 United States Antihypertensive Agents Sales Value by Type (%), 2024 VS 2031
6.3.3 United States Antihypertensive Agents Sales Value by Application, 2024 VS 2031
6.4 Europe
6.4.1 Europe Antihypertensive Agents Sales Value, 2020-2031
6.4.2 Europe Antihypertensive Agents Sales Value by Type (%), 2024 VS 2031
6.4.3 Europe Antihypertensive Agents Sales Value by Application, 2024 VS 2031
6.5 China
6.5.1 China Antihypertensive Agents Sales Value, 2020-2031
6.5.2 China Antihypertensive Agents Sales Value by Type (%), 2024 VS 2031
6.5.3 China Antihypertensive Agents Sales Value by Application, 2024 VS 2031
6.6 Japan
6.6.1 Japan Antihypertensive Agents Sales Value, 2020-2031
6.6.2 Japan Antihypertensive Agents Sales Value by Type (%), 2024 VS 2031
6.6.3 Japan Antihypertensive Agents Sales Value by Application, 2024 VS 2031
6.7 South Korea
6.7.1 South Korea Antihypertensive Agents Sales Value, 2020-2031
6.7.2 South Korea Antihypertensive Agents Sales Value by Type (%), 2024 VS 2031
6.7.3 South Korea Antihypertensive Agents Sales Value by Application, 2024 VS 2031
6.8 Southeast Asia
6.8.1 Southeast Asia Antihypertensive Agents Sales Value, 2020-2031
6.8.2 Southeast Asia Antihypertensive Agents Sales Value by Type (%), 2024 VS 2031
6.8.3 Southeast Asia Antihypertensive Agents Sales Value by Application, 2024 VS 2031
6.9 India
6.9.1 India Antihypertensive Agents Sales Value, 2020-2031
6.9.2 India Antihypertensive Agents Sales Value by Type (%), 2024 VS 2031
6.9.3 India Antihypertensive Agents Sales Value by Application, 2024 VS 2031
7 Company Profiles
7.1 Baxter International
7.1.1 Baxter International Profile
7.1.2 Baxter International Main Business
7.1.3 Baxter International Antihypertensive Agents Products, Services and Solutions
7.1.4 Baxter International Antihypertensive Agents Revenue (US$ Million) & (2020-2025)
7.1.5 Baxter International Recent Developments
7.2 Pfizer
7.2.1 Pfizer Profile
7.2.2 Pfizer Main Business
7.2.3 Pfizer Antihypertensive Agents Products, Services and Solutions
7.2.4 Pfizer Antihypertensive Agents Revenue (US$ Million) & (2020-2025)
7.2.5 Pfizer Recent Developments
7.3 Sandoz
7.3.1 Sandoz Profile
7.3.2 Sandoz Main Business
7.3.3 Sandoz Antihypertensive Agents Products, Services and Solutions
7.3.4 Sandoz Antihypertensive Agents Revenue (US$ Million) & (2020-2025)
7.3.5 Sandoz Recent Developments
7.4 Teva Pharmaceuticals
7.4.1 Teva Pharmaceuticals Profile
7.4.2 Teva Pharmaceuticals Main Business
7.4.3 Teva Pharmaceuticals Antihypertensive Agents Products, Services and Solutions
7.4.4 Teva Pharmaceuticals Antihypertensive Agents Revenue (US$ Million) & (2020-2025)
7.4.5 Teva Pharmaceuticals Recent Developments
7.5 Bayer
7.5.1 Bayer Profile
7.5.2 Bayer Main Business
7.5.3 Bayer Antihypertensive Agents Products, Services and Solutions
7.5.4 Bayer Antihypertensive Agents Revenue (US$ Million) & (2020-2025)
7.5.5 Bayer Recent Developments
7.6 Johnson & Johnson
7.6.1 Johnson & Johnson Profile
7.6.2 Johnson & Johnson Main Business
7.6.3 Johnson & Johnson Antihypertensive Agents Products, Services and Solutions
7.6.4 Johnson & Johnson Antihypertensive Agents Revenue (US$ Million) & (2020-2025)
7.6.5 Johnson & Johnson Recent Developments
7.7 Sun Pharmaceutical Industries
7.7.1 Sun Pharmaceutical Industries Profile
7.7.2 Sun Pharmaceutical Industries Main Business
7.7.3 Sun Pharmaceutical Industries Antihypertensive Agents Products, Services and Solutions
7.7.4 Sun Pharmaceutical Industries Antihypertensive Agents Revenue (US$ Million) & (2020-2025)
7.7.5 Sun Pharmaceutical Industries Recent Developments
7.8 Merck
7.8.1 Merck Profile
7.8.2 Merck Main Business
7.8.3 Merck Antihypertensive Agents Products, Services and Solutions
7.8.4 Merck Antihypertensive Agents Revenue (US$ Million) & (2020-2025)
7.8.5 Merck Recent Developments
7.9 AstraZeneca
7.9.1 AstraZeneca Profile
7.9.2 AstraZeneca Main Business
7.9.3 AstraZeneca Antihypertensive Agents Products, Services and Solutions
7.9.4 AstraZeneca Antihypertensive Agents Revenue (US$ Million) & (2020-2025)
7.9.5 AstraZeneca Recent Developments
7.10 Daiichi Sankyo
7.10.1 Daiichi Sankyo Profile
7.10.2 Daiichi Sankyo Main Business
7.10.3 Daiichi Sankyo Antihypertensive Agents Products, Services and Solutions
7.10.4 Daiichi Sankyo Antihypertensive Agents Revenue (US$ Million) & (2020-2025)
7.10.5 Daiichi Sankyo Recent Developments
7.11 Takeda
7.11.1 Takeda Profile
7.11.2 Takeda Main Business
7.11.3 Takeda Antihypertensive Agents Products, Services and Solutions
7.11.4 Takeda Antihypertensive Agents Revenue (US$ Million) & (2020-2025)
7.11.5 Takeda Recent Developments
7.12 Actelion
7.12.1 Actelion Profile
7.12.2 Actelion Main Business
7.12.3 Actelion Antihypertensive Agents Products, Services and Solutions
7.12.4 Actelion Antihypertensive Agents Revenue (US$ Million) & (2020-2025)
7.12.5 Actelion Recent Developments
7.13 Viatris
7.13.1 Viatris Profile
7.13.2 Viatris Main Business
7.13.3 Viatris Antihypertensive Agents Products, Services and Solutions
7.13.4 Viatris Antihypertensive Agents Revenue (US$ Million) & (2020-2025)
7.13.5 Viatris Recent Developments
7.14 United Therapeutics
7.14.1 United Therapeutics Profile
7.14.2 United Therapeutics Main Business
7.14.3 United Therapeutics Antihypertensive Agents Products, Services and Solutions
7.14.4 United Therapeutics Antihypertensive Agents Revenue (US$ Million) & (2020-2025)
7.14.5 United Therapeutics Recent Developments
7.15 Lupin Limited
7.15.1 Lupin Limited Profile
7.15.2 Lupin Limited Main Business
7.15.3 Lupin Limited Antihypertensive Agents Products, Services and Solutions
7.15.4 Lupin Limited Antihypertensive Agents Revenue (US$ Million) & (2020-2025)
7.15.5 Lupin Limited Recent Developments
7.16 Hikma Pharmaceuticals
7.16.1 Hikma Pharmaceuticals Profile
7.16.2 Hikma Pharmaceuticals Main Business
7.16.3 Hikma Pharmaceuticals Antihypertensive Agents Products, Services and Solutions
7.16.4 Hikma Pharmaceuticals Antihypertensive Agents Revenue (US$ Million) & (2020-2025)
7.16.5 Hikma Pharmaceuticals Recent Developments
7.17 Aurobindo Pharma
7.17.1 Aurobindo Pharma Profile
7.17.2 Aurobindo Pharma Main Business
7.17.3 Aurobindo Pharma Antihypertensive Agents Products, Services and Solutions
7.17.4 Aurobindo Pharma Antihypertensive Agents Revenue (US$ Million) & (2020-2025)
7.17.5 Aurobindo Pharma Recent Developments
7.18 Camber Pharmaceutical
7.18.1 Camber Pharmaceutical Profile
7.18.2 Camber Pharmaceutical Main Business
7.18.3 Camber Pharmaceutical Antihypertensive Agents Products, Services and Solutions
7.18.4 Camber Pharmaceutical Antihypertensive Agents Revenue (US$ Million) & (2020-2025)
7.18.5 Camber Pharmaceutical Recent Developments
7.19 Major Pharmaceuticals
7.19.1 Major Pharmaceuticals Profile
7.19.2 Major Pharmaceuticals Main Business
7.19.3 Major Pharmaceuticals Antihypertensive Agents Products, Services and Solutions
7.19.4 Major Pharmaceuticals Antihypertensive Agents Revenue (US$ Million) & (2020-2025)
7.19.5 Major Pharmaceuticals Recent Developments
7.20 Glenmark Pharmaceuticals
7.20.1 Glenmark Pharmaceuticals Profile
7.20.2 Glenmark Pharmaceuticals Main Business
7.20.3 Glenmark Pharmaceuticals Antihypertensive Agents Products, Services and Solutions
7.20.4 Glenmark Pharmaceuticals Antihypertensive Agents Revenue (US$ Million) & (2020-2025)
7.20.5 Glenmark Pharmaceuticals Recent Developments
7.21 Zydus Pharmaceuticals
7.21.1 Zydus Pharmaceuticals Profile
7.21.2 Zydus Pharmaceuticals Main Business
7.21.3 Zydus Pharmaceuticals Antihypertensive Agents Products, Services and Solutions
7.21.4 Zydus Pharmaceuticals Antihypertensive Agents Revenue (US$ Million) & (2020-2025)
7.21.5 Zydus Pharmaceuticals Recent Developments
7.22 Amneal Pharmaceuticals
7.22.1 Amneal Pharmaceuticals Profile
7.22.2 Amneal Pharmaceuticals Main Business
7.22.3 Amneal Pharmaceuticals Antihypertensive Agents Products, Services and Solutions
7.22.4 Amneal Pharmaceuticals Antihypertensive Agents Revenue (US$ Million) & (2020-2025)
7.22.5 Amneal Pharmaceuticals Recent Developments
7.23 Endo International
7.23.1 Endo International Profile
7.23.2 Endo International Main Business
7.23.3 Endo International Antihypertensive Agents Products, Services and Solutions
7.23.4 Endo International Antihypertensive Agents Revenue (US$ Million) & (2020-2025)
7.23.5 Endo International Recent Developments
7.24 Unichem Laboratories
7.24.1 Unichem Laboratories Profile
7.24.2 Unichem Laboratories Main Business
7.24.3 Unichem Laboratories Antihypertensive Agents Products, Services and Solutions
7.24.4 Unichem Laboratories Antihypertensive Agents Revenue (US$ Million) & (2020-2025)
7.24.5 Unichem Laboratories Recent Developments
7.25 Huahai Pharmaceutical
7.25.1 Huahai Pharmaceutical Profile
7.25.2 Huahai Pharmaceutical Main Business
7.25.3 Huahai Pharmaceutical Antihypertensive Agents Products, Services and Solutions
7.25.4 Huahai Pharmaceutical Antihypertensive Agents Revenue (US$ Million) & (2020-2025)
7.25.5 Huahai Pharmaceutical Recent Developments
7.26 Shijiazhuang Pharma Group
7.26.1 Shijiazhuang Pharma Group Profile
7.26.2 Shijiazhuang Pharma Group Main Business
7.26.3 Shijiazhuang Pharma Group Antihypertensive Agents Products, Services and Solutions
7.26.4 Shijiazhuang Pharma Group Antihypertensive Agents Revenue (US$ Million) & (2020-2025)
7.26.5 Shijiazhuang Pharma Group Recent Developments
7.27 Shanghai Shyndec Pharmaceutical
7.27.1 Shanghai Shyndec Pharmaceutical Profile
7.27.2 Shanghai Shyndec Pharmaceutical Main Business
7.27.3 Shanghai Shyndec Pharmaceutical Antihypertensive Agents Products, Services and Solutions
7.27.4 Shanghai Shyndec Pharmaceutical Antihypertensive Agents Revenue (US$ Million) & (2020-2025)
7.27.5 Shanghai Shyndec Pharmaceutical Recent Developments
8 Industry Chain Analysis
8.1 Antihypertensive Agents Industrial Chain
8.2 Antihypertensive Agents Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Raw Materials Key Suppliers
8.2.3 Manufacturing Cost Structure
8.3 Midstream Analysis
8.4 Downstream Analysis (Customers Analysis)
8.5 Sales Model and Sales Channels
8.5.1 Antihypertensive Agents Sales Model
8.5.2 Sales Channel
8.5.3 Antihypertensive Agents Distributors
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.1.1 Research Programs/Design
10.1.1.2 Market Size Estimation
10.1.1.3 Market Breakdown and Data Triangulation
10.1.2 Data Source
10.1.2.1 Secondary Sources
10.1.2.2 Primary Sources
10.2 Author Details
10.3 Disclaimer

 

ページTOPに戻る

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのご注文・お問合せはこちらのフォームから承ります

本レポートと同じKEY WORD(antihypertensive)の最新刊レポート

  • 本レポートと同じKEY WORDの最新刊レポートはありません。

よくあるご質問


QYResearch社はどのような調査会社ですか?


QYリサーチ(QYResearch)は幅広い市場を対象に調査・レポート出版を行う、中国に本社をおく調査会社です。   QYResearchでは年間数百タイトルの調査レポートを出版しています。... もっと見る


調査レポートの納品までの日数はどの程度ですか?


在庫のあるものは速納となりますが、平均的には 3-4日と見て下さい。
但し、一部の調査レポートでは、発注を受けた段階で内容更新をして納品をする場合もあります。
発注をする前のお問合せをお願いします。


注文の手続きはどのようになっていますか?


1)お客様からの御問い合わせをいただきます。
2)見積書やサンプルの提示をいたします。
3)お客様指定、もしくは弊社の発注書をメール添付にて発送してください。
4)データリソース社からレポート発行元の調査会社へ納品手配します。
5) 調査会社からお客様へ納品されます。最近は、pdfにてのメール納品が大半です。


お支払方法の方法はどのようになっていますか?


納品と同時にデータリソース社よりお客様へ請求書(必要に応じて納品書も)を発送いたします。
お客様よりデータリソース社へ(通常は円払い)の御振り込みをお願いします。
請求書は、納品日の日付で発行しますので、翌月最終営業日までの当社指定口座への振込みをお願いします。振込み手数料は御社負担にてお願いします。
お客様の御支払い条件が60日以上の場合は御相談ください。
尚、初めてのお取引先や個人の場合、前払いをお願いすることもあります。ご了承のほど、お願いします。


データリソース社はどのような会社ですか?


当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
世界各国の「市場・技術・法規制などの」実情を調査・収集される時には、データリソース社にご相談ください。
お客様の御要望にあったデータや情報を抽出する為のレポート紹介や調査のアドバイスも致します。



詳細検索

このレポートへのお問合せ

03-3582-2531

電話お問合せもお気軽に

 

2025/04/01 10:27

150.82 円

163.67 円

197.69 円

ページTOPに戻る